A new study suggests the gut microbiome may retain long-term signatures of past medication use, with some drugs leaving detectable effects years after treatment ends.

Nature Structural & Molecular Biology, Published online: 10 November 2025; doi:10.1038/s41594-025-01710-6He, Teng and Yang et al. report how metformin, the widely used antidiabetic drug, inhibit its target, the respiratory complex I, through a distinct state-dependent, inhibitor trapping mechanism, thus providing the molecular basis for its superior clinical tolerance.

Nature Structural & Molecular Biology, Published online: 10 November 2025; doi:10.1038/s41594-025-01710-6He, Teng and Yang et al. report how metformin, the widely used antidiabetic drug, inhibit its target, the respiratory complex I, through a distinct state-dependent, inhibitor trapping mechanism, thus providing the molecular basis for its superior clinical tolerance.

He, Teng and Yang et al. report how metformin, the widely used antidiabetic drug, inhibit its target, the respiratory complex I, through a distinct state-dependent, inhibitor trapping mechanism, thus ...

He, Teng and Yang et al. report how metformin, the widely used antidiabetic drug, inhibit its target, the respiratory complex I, through a distinct state-dependent, inhibitor trapping mechanism, thus ...

He, Teng and Yang et al. report how metformin, the widely used antidiabetic drug, inhibit its target, the respiratory complex I, through a distinct state-dependent, inhibitor trapping mechanism, thus ...

This is the first study using detailed retrospective medication usage data from electronic health records to systematically assess the long-term effects of medication usage on the gut microbiome. We i...

Diabetes mellitus is a chronic metabolic condition that requires tailored pharmacologic management. While **sulfonylureas** stimulate insulin secretion, **non-sulfonylurea drugs** work through different mechanisms, focusing on **insulin sensitivity, hepatic glucose production, and carbohydrate absorption**. Three major non-sulfonylurea drug classes are widely used: 1. **Biguanides** – Metformin 2. **α-Glucosidase Inhibitors** – Acarbose, Miglitol 3. **Thiazolidinediones (Glitazones)** – Pioglitazone, Rosiglitazone These drugs are especially important in **type 2 diabetes mellitus (T2DM)** , where insulin resistance is a key problem. ## **How They Work – Mechanisms of Action** ### **Metformin (Biguanide Class)** **Primary action** : Reduces hepatic glucose production. **Mechanism** : * Sensitizes the liver to circulating insulin levels. * Inhibits gluconeogenesis (glucose production from non-carbohydrate sources). * Enhances peripheral glucose uptake and utilization. **Bonus effect** : Modest weight loss and lipid profile improvement. ### **α-Glucosidase Inhibitors (Acarbose, Miglitol)** **Primary action** : Delays carbohydrate absorption in the intestine. **Mechanism** : * Inhibits the enzyme α-glucosidase in the small intestine. * Slows breakdown of complex carbohydrates into glucose. * Blunts post-meal blood sugar spikes. **Key point** : No effect on fasting glucose; primarily lowers **postprandial glucose**. ### **Thiazolidinediones (Glitazones) – Pioglitazone, Rosiglitazone** **Primary action** : Improves insulin sensitivity in muscle and adipose tissue. **Mechanism** : * Activates peroxisome proliferator-activated receptor gamma (**PPAR-γ**) in the nucleus. * Decreases insulin resistance. * Reduces hepatic glucose output. * Increases insulin-dependent glucose uptake. ## **Indications** * **Type 2 Diabetes Mellitus** when diet and exercise alone are inadequate. * Often used in **combination therapy** with sulfonylureas or insulin. * Preferred in **overweight patients** (especially metformin) due to weight-neutral or weight-loss benefits. * Useful in controlling **postprandial hyperglycemia** (α-glucosidase inhibitors). * As an **insulin-sensitizing agent** in metabolic syndrome and polycystic ovary syndrome (metformin). ## **Contraindications & Cautions** ### **Metformin** * Severe renal impairment (risk of lactic acidosis) * Acute or chronic metabolic acidosis (including ketoacidosis) * Heart failure (unstable or acute) * Hepatic impairment * Age > 80 years without adequate renal function testing * Pregnancy (safety data limited) ### **Thiazolidinediones** * Symptomatic heart failure (can cause fluid retention) * Active liver disease ## **Adverse Reactions** ### **Metformin** * **Gastrointestinal upset** : Metallic taste, bloating, nausea, diarrhea. * **Lactic acidosis** : Rare but potentially fatal. * Possible **weight loss** (beneficial for some patients). ### **α-Glucosidase Inhibitors** * GI effects: Flatulence, diarrhea, abdominal discomfort. * Hypoglycemia risk only if combined with insulin or sulfonylureas — and must be treated with **pure glucose** (sucrose absorption is blocked). ### **Thiazolidinediones** * Fluid retention, edema. * Upper respiratory infections, sinusitis. * Headache, myalgia, back pain. * Rare risk of bladder cancer (pioglitazone). * May cause weight gain. ## **Lactic Acidosis – A Serious Concern with Metformin** * **Definition** : Excess lactic acid in the blood, leading to metabolic acidosis. * **Risk factors** : Renal dysfunction, hypoxia, sepsis, dehydration. * **Symptoms** : Malaise, abdominal pain, rapid breathing, muscle pain, decreased vitamin B12 levels. * **Management** : Immediate discontinuation of metformin, supportive care, correction of acidosis, B12 supplementation if needed. ## **Drug Interactions** * **Metformin + Corticosteroids** → Increased risk of hyperglycemia and lactic acidosis. * **Miglitol + Digestive Enzymes** → Reduced effectiveness. * **Thiazolidinediones + Insulin** → Increased risk of edema and heart failure. ## **Nursing Management & Patient Education** * Stop metformin **48 hours before and after radiologic studies** using contrast. * Temporarily discontinue before surgical procedures. * Take as directed — usually with meals to reduce GI upset. * Explain that these drugs **do not replace insulin** in type 1 diabetes. * Never adjust the dose without medical supervision. * Take at the **same time each day** for stable blood levels. * Educate hypoglycemic patients on α-glucosidase inhibitors to use **glucose tablets** (not sucrose). * Monitor for signs of lactic acidosis and report immediately. ## **Dosage & Routes – Quick Table** Generic| Trade Name| Safe Dose & Indication| Route ---|---|---|--- Acarbose| Precose| 25–100 mg orally TID with meals for postprandial control| Oral Metformin| Glucophage, Riomet| 500–3000 mg/day in divided doses for glycemic control| Oral Pioglitazone| Actos| 5–15 mg orally daily in combination with metformin or sulfonylurea| Oral ## **Summary Table – Class Comparison** Class| Example Drugs| Main Action| Key Benefits| Major Risks ---|---|---|---|--- Biguanide| Metformin| ↓ Hepatic glucose production| Weight neutral/loss, low hypo risk| Lactic acidosis, GI upset α-Glucosidase inhibitor| Acarbose, Miglitol| ↓ Carb absorption in gut| Post-meal glucose control| GI discomfort, flatulence Thiazolidinedione| Pioglitazone| ↑ Insulin sensitivity| Improves muscle glucose uptake| Edema, heart failure risk ## **FAQs** **1. Can metformin be used in type 1 diabetes?** No, it is ineffective without endogenous insulin production. **2. Why should metformin be stopped before contrast studies?** To avoid lactic acidosis risk in case of contrast-induced kidney injury. **3. How should hypoglycemia be treated in a patient on acarbose?** With pure glucose tablets or dextrose — not sucrose. **4. Do thiazolidinediones cause low blood sugar?** No, unless combined with other hypoglycemic agents. **5. Is weight gain possible with pioglitazone?** Yes, due to fluid retention and fat redistribution.